1st Sub. S.B. 41 DRUG UTILIZATION REVIEW BOARD AMENDMENTS

HOUSE FLOOR AMENDMENTS

AMENDMENT 2

FEBRUARY 24, 2010 10:53 AM

Representative **Paul Ray** proposes the following amendments:

```
1. Page 3, Lines 70 through 78
   House Committee Amendments
   2-22-2010:
  70
                (2) \hat{H} \rightarrow \{+\} (a) \{+\} \leftarrow \hat{H} \{-\frac{The}{The}\}
                                                                    Except as provided in Subsection (2)(b), the board
         may, \hat{H} \rightarrow [when the board determines it is appropriate]
         Ĥ→ only ←Ĥ after
70a1
 70a
         complying with Subsections (1)(b) through (j) \leftarrow \hat{H}, consider the cost:
                                             \{ (a) \} \leftarrow \hat{H} of a drug when placing a drug on the prior approval program;
  71
                Ĥ→ {+} (i) {+}
         and
                \hat{H} \rightarrow \{+\} (ii) \{+\} \{-\} \{-\} \{-\} associated with including, or excluding a drug from the prior
  72
         approval
 72a
         process,
  73
         including:
  74
                \hat{H} \rightarrow [(A)]  \{\underline{(i)}\} (A) \leftarrow \hat{H} potential side effects associated with a drug; or
  75
                Ĥ→ [<del>(B)</del>] {<del>-(ii)</del>}
                                        (B) ←Ĥ potential hospitalizations or other complications that may occur as a
         result
 75a
         of a
  76
         drug's inclusion on the prior approval process.
  77
                Ĥ→ [(b) If the board considers the cost of a drug under Subsection (2)(a), the provisions of
         Subsections (1)(b) through (j) apply. | ←Ĥ
  78
                (b) The board may not consider the cost of a psychotropic or anti-psychotic drug under the
         provisions of this section.
```